SSI Strategy
SSI Strategy
  • 48
  • 4 047
Ep. 40 Supercharging Biotechs: The Power of Strategic Board Engagement
How can biotech CEOs and their boards foster strong, trusting relationships that drive effective decision-making and long-term success? In this episode of Emerging Biotech Leader, host Kim Kushner explores this critical question together with Don de Bethizy. Don is a seasoned life sciences executive with over 30 years of experience, having served as a founder and CEO as well as board member and advisor.
The episode highlights key strategies for building trust, setting clear objectives, and managing board relationships, making it essential listening for anyone looking to enhance their leadership approach in the biotech industry. Here you’ll find actionable advice that can significantly impact your company’s success and your own professional growth.
Key takeaways include:
The delicate balance of board relations: Don stresses the importance of transparency with the board while maintaining a strategic focus.
Building the right team: "Get the right people on the bus, but in the right seats," Don advises. He discusses the challenges of early hiring decisions and the need to make tough choices quickly when someone isn't the right fit.
Leveraging board expertise: Don highlights the value of specialized committees, like R&D, to dive deeper into critical areas without bogging down full board meetings.
Throughout the discussion, Don's humility and willingness to learn shine through. He candidly shares mistakes and lessons learned, offering a refreshing perspective on leadership growth.
Tune in to gain a deeper understanding of what it takes to successfully manage board relationships, refine your strategic focus, and build a culture of accountability and trust within your organization.
Are you leading a biotech and would like to share your experience with our podcast audience? We'd love to hear from you!
มุมมอง: 16

วีดีโอ

EU HTA Regulation Insights: Expert Strategies for Success
มุมมอง 3216 ชั่วโมงที่ผ่านมา
The European Union's healthcare landscape is on the verge of a significant transformation with the impending implementation of the new Health Technology Assessment (HTA) regulation. Set to take effect in 2025, this regulation aims to harmonize the clinical assessment process across EU member states, potentially streamlining market access for new drugs and medical devices. However, it also intro...
Ep. 39 How Smart Risk Management Safeguards Your Biotech Venture
มุมมอง 3014 วันที่ผ่านมา
In this episode of "The Emerging Biotech Leader" podcast, host Ramin Frahood speaks with Helen Kargaryani, VP Global Head of Quality/Quality Services at SSI Strategy. With over 30 years of experience in the pharmaceutical and biotech industries, Helen shares her expertise on quality and risk management. Risk management in these industries is a critical process that helps companies identify, pri...
Ep. 38 Where Risk Meets Opportunity: Strategies for MedTech Success
มุมมอง 4728 วันที่ผ่านมา
This episode offers critical insights on leveraging risk management as a strategic advantage in medical device development. In a conversation with Ramin Farhood, Bijan Elahi, with over 30 years of experience, provides a roadmap for integrating safety considerations into innovation pipelines, potentially accelerating time-to-market and enhancing competitive positioning. Key Strategic Takeaways: ...
Ep. 37 Patients as Partners: A Winning Strategy for Drug Development
มุมมอง 35หลายเดือนก่อน
The latest Emerging Biotech Leader podcast tackles the important topic of patient-focused drug development, offering valuable insights for the biotech industry. Our host Kim Kushner engages in an insightful dialogue with Dr. Laurie Smaldone-Alsup, SVP Regulatory Science at SSI Strategy, who brings years of hands-on regulatory experience to the conversation. Laurie’s career, spanning from pionee...
Ep. 36 Rare Diseases, Real Lives: Bridging Patient Needs and Drug Development
มุมมอง 122 หลายเดือนก่อน
On this episode of Emerging Biotech Leader, Kim Kushner sits down with Edward M Kaye, M.D., CEO and director of Stoke Therapeutics, to talk about his work in rare disease drug development. Throughout their conversation, Ed describes the challenges of first-in-class drug development. He explains the importance of understanding diseases thoroughly and the value of natural history studies. He also...
EU HTA Regulation: What’s changing & why it matters!
มุมมอง 832 หลายเดือนก่อน
The new EU Health Technology Assessment (HTA) Regulation aims to harmonize and facilitate HTA evaluations across EU member states by introducing a mandatory joint clinical assessment (JCA) at the EU level, supported by an optional joint scientific consultation (JSC) process. The Regulation represents a significant shift, particularly in terms of timing and evidence requirements for pharmaceutic...
Ep. 35 Real-World Evidence and Putting Patients at the Center of Drug Development
มุมมอง 142 หลายเดือนก่อน
In this episode, host Kim Kushner is joined by Dr. Chantal van Gils, a leading expert in evidence and value strategy at SSI Strategy. Building on the previous podcast discussion with Christian Howell of Cognito, this episode delves into three key themes: 1) differing evidentiary requirements for medical devices versus pharmaceuticals, 2) the critical importance of patient-focused drug developme...
Ep. 34 Daring to Fail Forward: The Mindset Catalyzing Healthcare Breakthroughs
มุมมอง 143 หลายเดือนก่อน
This episode features an interview with Christian Howell, Chief Commercial Officer at Cognito Therapeutics, a biotech company pioneering a neurotechnology approach to treat Alzheimer's disease. Christian draws on his diverse background spanning the military, medical device giant Medtronic, and now the biotech industry. The conversation covers Cognito's evidence generation strategy to demonstrat...
Ep. 33 Avoiding Common Pitfalls in the Biotech Development Process
มุมมอง 593 หลายเดือนก่อน
In this podcast, Ramin Farhood hosts Dr. Thomas Lönngren, an expert in drug regulation, approval, and market access. Thomas has an impressive career spanning over three decades, including a transformative tenure as the executive director of the European Medicines Agency (EMA). He currently serves as a strategic advisor, leveraging his experience to guide pharmaceutical companies and biotech thr...
Ep. 32 Redefining Roles: From Medical Practice to Biotech Ventures
มุมมอง 924 หลายเดือนก่อน
In this episode of the Emerging Biotech Leader podcast, hosts Kim Kushner and Ramin Farhood interview Keith Gottesdiener, President and CEO of Prime Medicine. They discuss Keith's unconventional career path, which spans roles as a physician, research scientist, drug development leader at Merck for over 16 years, and entrepreneurial biotech CEO at Rhythm Pharmaceuticals before joining Prime Medi...
Ep. 31 Balancing Current Needs and Long-Term Goals in Biotech
มุมมอง 224 หลายเดือนก่อน
In this engaging episode of the Emerging Biotech Leader podcast, Kim Kushner, Ramin Farhood, and Jackie Levine discuss the key lessons learned from the previous conversation with Dr. Dan Bloomfield, CMO at Anthos Therapeutics. The trio focus on the challenges biotech companies face when building organizations with evolving goals, the important role of leaders as connectors, and the magnitude of...
Ep. 30 Growing Early Biotech Startups through Connection
มุมมอง 465 หลายเดือนก่อน
In this episode of the Emerging Biotech Leader podcast, hosts Kim Kushner and Ramin Farhad speak with Dr. Dan Bloomfield, Chief Medical Officer of Anthos Therapeutics. Dan generously shares insights from his diverse career that has spanned academia at Columbia University, over a decade at big pharma giant Merck across multiple leadership roles, and most recently entrepreneurial biotech startups...
Ep. 29 Lessons in Biotechs with Bold Missions
มุมมอง 157 หลายเดือนก่อน
In this episode of the Emerging Biotech Leader podcast, hosts Kim Kushner and Ramin Farhad are joined by Bob Honigberg to further discuss the considerable challenge of achieving bold missions in healthcare. Building on their discussion from Episode 28 where they interviewed Clearly Health founder Dr. Jim Ninh, the episode provides useful perspectives for any mission-driven biotech seeking to pr...
Ep. 28 Lessons in Clinical Trials with the Unlikely Entrepreneur ft. Jim Min
มุมมอง 528 หลายเดือนก่อน
"I believe that we can eradicate heart attacks from this world...If we can leverage these tools to accomplish those three goals, whether it's in coronary heart disease, valvular heart disease, myocardial disease, et cetera, et cetera, I think that's going to not be a slight improvement. I think it's going to be a game changer in terms of improving patient care and outcomes." ~ Jim Min, Founder ...
Ep. 27: How do you build an outcome-driven Biotech?
มุมมอง 2898 หลายเดือนก่อน
Ep. 27: How do you build an outcome-driven Biotech?
SSI Season's Greetings
มุมมอง 7310 หลายเดือนก่อน
SSI Season's Greetings
Ep. 26: Recalibrating Early Stages of Corporate Build ft. Johan Stromquist
มุมมอง 2810 หลายเดือนก่อน
Ep. 26: Recalibrating Early Stages of Corporate Build ft. Johan Stromquist
Building on Early Successes: Optimizing Preclinical Programs and Streamlining Clinical Translation
มุมมอง 8110 หลายเดือนก่อน
Building on Early Successes: Optimizing Preclinical Programs and Streamlining Clinical Translation
Ep. 25 When's The Best Time To Think About Safety? It's Now FT. Greg Fiore & Amit Patel
มุมมอง 2010 หลายเดือนก่อน
Ep. 25 When's The Best Time To Think About Safety? It's Now FT. Greg Fiore & Amit Patel
Ep. 24 Cultivating a Culture of Safety Ft. Dr. Jason Campagna
มุมมอง 3911 หลายเดือนก่อน
Ep. 24 Cultivating a Culture of Safety Ft. Dr. Jason Campagna
Webinar: De risking Development Strategies to Achieve Biotech Milestones
มุมมอง 9411 หลายเดือนก่อน
Webinar: De risking Development Strategies to Achieve Biotech Milestones
Ep. 23 Launch & Leadership in Early Biotech
มุมมอง 7711 หลายเดือนก่อน
Ep. 23 Launch & Leadership in Early Biotech
Ep. 22 The Myth of The Industry Sellout ft. Benit Maru
มุมมอง 49ปีที่แล้ว
Ep. 22 The Myth of The Industry Sellout ft. Benit Maru
Ep. 21 Following a Drug Through Development in Pursuit of a Passion
มุมมอง 82ปีที่แล้ว
Ep. 21 Following a Drug Through Development in Pursuit of a Passion
Ep. 20 - Changing the Patient Care Paradigm ft. Leah Damesek
มุมมอง 34ปีที่แล้ว
Ep. 20 - Changing the Patient Care Paradigm ft. Leah Damesek
Ep. 19: Bringing Paradigm Changing Devices to Market ft. Shon Chakrabarti
มุมมอง 57ปีที่แล้ว
Ep. 19: Bringing Paradigm Changing Devices to Market ft. Shon Chakrabarti
Ep. 18: Pioneering with Patients First Ft. Kate Goldstein
มุมมอง 41ปีที่แล้ว
Ep. 18: Pioneering with Patients First Ft. Kate Goldstein
Ep. 17: Pioneering in the Emerging Field of Digital Therapeutics ft. Scott Xiao
มุมมอง 233ปีที่แล้ว
Ep. 17: Pioneering in the Emerging Field of Digital Therapeutics ft. Scott Xiao
Ep. 16: How to Juggle Priorities as a CMO ft. Hootan Khatami
มุมมอง 40ปีที่แล้ว
Ep. 16: How to Juggle Priorities as a CMO ft. Hootan Khatami

ความคิดเห็น

  • @ian3128
    @ian3128 10 หลายเดือนก่อน

    Promo*SM

  • @douglaslocke5381
    @douglaslocke5381 ปีที่แล้ว

    Really enjoyed - shift from big pharma to nascent office…physician leader

  • @allyson2527
    @allyson2527 ปีที่แล้ว

    😇 promo sm

  • @luckybaring3907
    @luckybaring3907 2 ปีที่แล้ว

    Well done. Very proud of you. I met you in 1985 in Sri Lanka with Shivantha. Great achievement. Raji 🙏 🌹

  • @luckybaring3907
    @luckybaring3907 2 ปีที่แล้ว

    Well done Suku. From Raji